Home Interviews BioStock Studio: Hemcheck’s CEO on the company’s progress

BioStock Studio: Hemcheck’s CEO on the company’s progress

BioStock Studio: Hemcheck’s CEO on the company’s progress

1 July, 2021

Blood analysis is one of the most frequently performed clinical routines in modern medical care. Hemolysis is one of the most common errors affecting blood test results, and it leads to delayed treatment for the patients and increased costs for the healthcare system.  Swedish medtech company Hemcheck has developed a concept to detect hemolysis in blood samples through a range of products and services offered to healthcare providers, thus contributing to better care flow, reduced costs and, above all, increased patient safety. CEO Joen Averstad visited the BioStock Studio to tell us more about the company and its upcoming milestones.

Watch the interview with Hemcheck‘sCEO Joen Averstad below:

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev